BillionToOne study finds Northstar Response ctDNA test outperforms imaging in predicting immunotherapy outcomes

BillionToOne

BillionToOne

BLLN

0.00
  • BillionToOne disclosed peer-reviewed study results on June 29, 2026; findings were already published, not flagged for a future presentation.
  • Northstar Response blood-based monitoring predicted immunotherapy outcomes more reliably than standard imaging across advanced solid tumors.
  • Combining molecular monitoring with imaging sharpened risk stratification, helping flag likely non-responders even when scans read as stable disease.
  • Serial testing detected progression earlier than clinicoradiographic assessment, creating a potential window to adjust surveillance or treatment strategy sooner.
  • Results were reproduced in a separate prospective validation cohort, supporting broader clinical adoption for immunotherapy monitoring.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA94395) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.